Anna Linda Zignego Selected Research

Anna Linda Zignego Research Topics

Disease

31	Infections 06/2021 - 10/2002
26	Cryoglobulinemia 01/2021 - 08/2003
18	Vasculitis (Vasculitides) 10/2022 - 12/2007
12	Liver Diseases (Liver Disease) 02/2019 - 09/2007
11	Fibrosis (Cirrhosis) 01/2020 - 04/2006
8	Chronic Hepatitis C 05/2021 - 09/2007
7	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 11/2020 - 11/2005
6	Lymphoma (Lymphomas) 12/2022 - 09/2011
6	Neoplasms (Cancer) 11/2020 - 11/2005
6	Hepatitis C 10/2018 - 08/2013
4	COVID-19 01/2022 - 01/2021
4	Hepatitis 01/2022 - 01/2014
4	Disease Progression 01/2021 - 06/2014
4	Liver Cirrhosis (Hepatic Cirrhosis) 09/2018 - 09/2007
4	Virus Diseases (Viral Diseases) 01/2018 - 09/2007
4	Persistent Infection 11/2017 - 01/2011
3	Non-Hodgkin Lymphoma (Lymphosarcoma) 10/2022 - 01/2013
3	Hepatocellular Carcinoma (Hepatoma) 01/2021 - 07/2002
3	Systemic Vasculitis 09/2018 - 06/2004
3	Carcinogenesis 10/2015 - 01/2009
2	Mental Disorders (Mental Disorder) 01/2022 - 01/2014
2	Sjogren's Syndrome (Sjogren Syndrome) 01/2022 - 03/2017
2	Rheumatic Diseases (Rheumatism) 06/2021 - 01/2017
2	Rheumatoid Arthritis 01/2021 - 01/2020
2	Inflammation (Inflammations) 01/2020 - 09/2007
2	Anemia 11/2016 - 03/2016
2	Hemophilia A (Haemophilia) 06/2014 - 03/2014
2	Autoimmune Diseases (Autoimmune Disease) 01/2013 - 11/2005
1	Clinical Deterioration 01/2022
1	Interstitial Lung Diseases (Interstitial Lung Disease) 12/2021
1	Hematologic Neoplasms (Hematological Malignancy) 12/2020
1	Hypertension (High Blood Pressure) 10/2018
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 09/2018
1	B-Cell Lymphoma (Lymphoma, B Cell) 09/2018
1	Chronic Hepatitis B 07/2017

Drug/Important Bio-Agent (IBA)

30	Antiviral Agents (Antivirals)IBA 12/2022 - 10/2002
14	Rituximab (Mabthera)FDA Link 12/2021 - 09/2007
10	CryoglobulinsIBA 01/2021 - 03/2015
9	InterferonsIBA 10/2018 - 08/2003
8	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2013
8	Ribavirin (Virazole)FDA LinkGeneric 10/2018 - 08/2003
5	Rheumatoid FactorIBA 01/2022 - 03/2017
5	MicroRNAs (MicroRNA)IBA 11/2020 - 01/2012
5	Antigen-Antibody Complex (Immune Complex)IBA 01/2017 - 06/2004
4	Biological ProductsIBA 01/2021 - 09/2007
4	Immunoglobulin G (IgG)IBA 01/2021 - 11/2017
4	RNA (Ribonucleic Acid)IBA 08/2016 - 08/2003
3	Antirheumatic Agents (DMARD)IBA 01/2022 - 01/2021
3	Proteins (Proteins, Gene)FDA Link 01/2020 - 07/2002
3	Pharmaceutical PreparationsIBA 01/2018 - 09/2014
3	DNA (Deoxyribonucleic Acid)IBA 07/2016 - 06/2004
3	CytokinesIBA 08/2013 - 12/2004
2	B-Cell Activating FactorIBA 10/2022 - 01/2017
2	SteroidsIBA 01/2022 - 01/2017
2	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2022 - 01/2021
2	NucleotidesIBA 01/2021 - 07/2017
2	NucleosidesIBA 01/2021 - 07/2017
2	dasabuvirIBA 10/2018 - 01/2017
2	Ritonavir (Norvir)FDA Link 10/2018 - 01/2017
2	paritaprevirIBA 10/2018 - 01/2017
2	ombitasvirIBA 10/2018 - 01/2017
2	AutoantibodiesIBA 09/2018 - 03/2015
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2017 - 01/2017
2	telaprevirIBA 03/2016 - 01/2014
2	N- (3- amino- 1- (cyclobutylmethyl)- 2,3- dioxopropyl)- 3- (2- ((((1,1- dimethylethyl)amino)carbonyl)amino)- 3,3- dimethyl- 1- oxobutyl)- 6,6- dimethyl- 3- azabicyclo(3.1.0)hexan- 2- carboxamideIBA 09/2014 - 01/2014
2	CXC ChemokinesIBA 08/2013 - 11/2012
2	Interleukin-6 (Interleukin 6)IBA 08/2013 - 01/2011
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 08/2013 - 01/2011
2	LigandsIBA 08/2013 - 11/2012
2	Viral ProteinsIBA 01/2012 - 01/2009
2	Monoclonal AntibodiesIBA 09/2011 - 09/2007
1	B-Cell Activation Factor ReceptorIBA 10/2022
1	VaccinesIBA 12/2021
1	GlucocorticoidsIBA 12/2021
1	Mycophenolic Acid (Cellcept)FDA LinkGeneric 12/2021
1	Hepatitis B Surface Antigens (HBsAg)FDA Link 06/2021
1	Immunosuppressive Agents (Immunosuppressants)IBA 06/2021
1	glecaprevir and pibrentasvirIBA 05/2021
1	Biosimilar PharmaceuticalsIBA 01/2021
1	nasIBA 01/2021
1	CT-P10IBA 01/2021
1	Messenger RNA (mRNA)IBA 01/2021
1	Genetic Markers (Genetic Marker)IBA 01/2021
1	Notch ReceptorsIBA 12/2020
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2020
1	velpatasvirIBA 10/2018
1	SofosbuvirIBA 10/2018
1	AlbuminsIBA 10/2018
1	Immunoglobulin M (IgM)IBA 09/2018

Therapy/Procedure

28	Therapeutics 01/2022 - 10/2002
5	Kidney Transplantation 02/2019 - 08/2012
4	Renal Dialysis (Hemodialysis) 02/2019 - 10/2018
2	Ambulatory Care (Outpatient Care) 01/2019 - 05/2018
2	Liver Transplantation 01/2019 - 05/2018
2	Drug Therapy (Chemotherapy) 09/2018 - 08/2012
2	Retreatment 01/2017 - 09/2015
2	Aftercare (After-Treatment) 09/2007 - 05/2006
1	Precision Medicine 01/2021
1	Immunotherapy 01/2018
1	Treatment Delay 12/2017